politics
The FDA's data on mifepristone can't be trusted — here's why
Why this matters: political developments that affect policy direction and public trust.
For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.
Read full story on The Hill → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from The Hill alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop